| Target Molecule | Ziconotide Acetate (ω-Conotoxin MVIIA) |
| Synonyms | Ziconotide, ω-Conotoxin MVIIA, SNX-111, Prialt |
| CAS Number | 107452-89-1 (ziconotide base); supplied as acetate salt |
| Sequence (3-Letter) | H-Cys-Lys-Gly-Lys-Gly-Ala-Lys-Cys-Ser-Arg-Leu-Met-Tyr-Asp-Cys-Cys-Thr-Gly-Ser-Cys-Arg-Ser-Gly-Lys-Cys-NH₂ (cyclic disulfides Cys1–Cys16, Cys8–Cys20, Cys15–Cys25) |
| Sequence (1-Letter) | CKGKGAKCSRLMYDCCTGSCRSGKC-NH₂ (3 disulfides: 1–16, 8–20, 15–25; ICK motif) |
| Molecular Formula | C₁₀₂H₁₇₂N₃₆O₃₂S₇ (free base) |
| Molecular Weight | 2639.18 (free base) |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥98%, ≥99% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate (standard pharmaceutical form), TFA, or custom salt options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) and Regioselective Disulfide Folding |
| Modification Options | Inhibitor cystine-knot (ICK) stabilization, stable isotope labeling (13C, 15N), scrambled isomer impurity standards |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and disulfide connectivity verification provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Ziconotide Acetate (CAS 107452-89-1) is a 25-amino-acid conotoxin containing six cysteines folded into a rigid inhibitor cystine-knot (ICK) motif. We target this sequence to supply high-purity reference materials and raw materials for N-type calcium channel and pain pathway research.
We utilize optimized solid-phase peptide synthesis (SPPS) and orthogonal cystine-protecting groups. Our peptide synthesis platform ensures precise chain elongation and sequential, directed oxidation to selectively form the Cys1–Cys16, Cys8–Cys20, and Cys15–Cys25 disulfide bridges, preventing inactive scrambled isomers.
Yes. We provide specialized peptide modification services for ICK peptides. Options include the synthesis of misfolded scrambled isomers as impurity reference standards, site-specific stable isotope labeling (13C, 15N) for quantitative LC-MS/MS, and fluorescent tagging.
Our manufacturing infrastructure scales production from milligram-level analytical batches to kilogram-level commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (ensuring acetate salt conversion) to guarantee strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, disulfide verification, impurity profiling, analytical method validation, and regulatory documentation to support complex drug development pipelines.
Ziconotide Acetate, the synthetic form of omega-conotoxin MVIIA (CAS 107452-89-1), is a 25-residue peptide acting as a selective N-type voltage-gated calcium channel (Cav2.2) blocker. Synpeptide provides comprehensive synthetic solutions for this molecule, utilizing its structural complexity to demonstrate our advanced capabilities in regioselective folding and pharmaceutical peptide manufacturing.
Constructing a peptide with six cysteine residues and an ICK architecture requires exact control over chain elongation and sequential ring closure. Our custom peptide synthesis platform utilizes optimized Solid-Phase Peptide Synthesis (SPPS) protocols combined with orthogonal protecting group strategies. This systematic approach ensures high-fidelity assembly of the 25-residue backbone, consistently delivering raw materials with stringent purity profiles (typically ≥98% via HPLC) for advanced research.
The biological activity of Ziconotide depends strictly on the precise pairing of Cys1–Cys16, Cys8–Cys20, and Cys15–Cys25. Standard random oxidation methods fail to yield the correct topology. Through our peptide modification services, we execute directed oxidation cascades and verify disulfide connectivity using high-resolution LC-MS/MS, reduction-alkylation assays, and comparative peptide mapping.
Transitioning a triple-disulfide peptide from analytical scale to commercial volumes presents significant engineering challenges. We execute large-scale peptide synthesis for Ziconotide by optimizing liquid-phase handling, high-capacity preparative HPLC purification, and controlled lyophilization. This infrastructure guarantees a stable supply chain, smoothly scaling from milligram research quantities to kilogram commercial batches with exact lot-to-lot reproducibility.
We provide structural engineering and manufacturing capacity as a fully integrated peptide CDMO. Our technical teams support pharmaceutical developers through process optimization, rigorous stability assessments, and complete analytical documentation. We deliver the precise data and scalable manufacturing required to advance complex peptide APIs through the development lifecycle.
